Annual Meeting Program - Society of Toxicology

Society of Toxicology 2012
Program Description (Continued)
Abstract #
#28 10:24 BILE ACID AND NUCLEAR RECEPTOR
SIGNALING IN DIABETES AND OBESITY. ​
J. Chiang. Colleges of Medicine and Pharmacy,
Northeastern Ohio Universities, Rootstown, OH.
Sponsor: A. Slitt.
#29 10:56 HEPATOBILIARY TRANSPORTER
REGULATION IN DIABETIC PREGNANCY:
INFLUENCE OF NRF2 AND FXR-SHP
SIGNALING. ​L. M. Aleksunes. Department of
Pharmacology and Toxicology, Rutgers, Ernest Mario
School of Pharmacy, Piscataway, NJ.
#30 11:28 REVERSING OBESITY AND METABOLIC
SYNDROME: DO NUCLEAR RECEPTORS
HAVE A ROLE IN WEIGHT LOSS? ​A. L. Slitt.
Biomedical and Pharmaceutical Sciences, University
of Rhode Island, Kingston, RI.
Monday Morning, March 12
9:15 AM to 12:00 Noon
Room 102
​Aberrant Gene Expression in Toxicity and Disease—
Epigenetics and microRNAs
Symposium Session: Toxicological Considerations of
Epigenetic Targets in Product Development
Chairperson(s): Melissa Rhodes, GlaxoSmithKline, Research Triangle Park,
NC, and Brandon D. Jeffy, Celgene, San Diego, CA.
Sponsor:
Drug Discovery Toxicology Specialty Section
Endorsed by:
Carcinogenesis Specialty Section
Mechanisms Specialty Section
Molecular Biology Specialty Section
Regulatory and Safety Evaluation Specialty Section
Reproductive and Development Toxicology Specialty Section
In recent years, epigenetic factors have been implicated in the etiology of
various diseases including cancers, psychiatric disorders, and diabetes/
obesity. As epigenetic mechanisms have become more extensively characterized,
new opportunities for therapeutic intervention in these disease areas
have been identified. While pharmaceutical inhibitors of epigenetic targets
such as histone deacetylases and DNA methyltransferases have recently
gained regulatory approval, the field of pharmacoepigenetics is still relatively
young. As greater understanding of the epigenome is evolving, previously
approved drugs are now serendipitously being found to have epigenetic
modulatory properties and are currently under evaluation for new indications.
With the rapid emergence of multiple novel epigenetic targets for
pharmacological inhibition, new considerations for the field of toxicoepigenetics
are becoming apparent as well. In order to address the potential
toxicological consequences associated with pharmacological inhibition of
potential therapeutic epigenetic targets, toxicologists are addressing the need
for new models and endpoints to be considered in the safety assessment
of epigenetic targets. These important toxicological issues, which may be
unique to epigenetic targets, will be addressed.
#31 9:15 TOXICOLOGICAL CONSIDERATIONS
OF EPIGENETIC TARGETS IN PRODUCT
DEVELOPMENT. ​B. D. Jeffy 1 , and M. Rhodes 2 .
1
Exploratory Toxicology, Celgene, San Diego, CA,
and 2 Safety Assessment Project Development,
GlaxoSmithKline, Research Triangle Park, NC.
9:15 INTRODUCTION. ​Brandon D. Jeffy
Abstract #
#32 9:20 EPIGENETICS MEETS TOXICOLOGY: AN
INTEGRATED VIEW OF MECHANISMS
CONTROLLING TRANSCRIPTION THAT ARE
SUPERIMPOSED ON DNA BASE SEQUENCE. ​
J. Goodman. Pharmacology/Toxicology, Michigan
State University, East Lansing, MI.
#33 9:52 EVALUATION OF POTENTIAL SAFETY RISKS
OF PHARMACOLOGICAL INHIBITORS
OF EPIGENETIC TARGETS IN DISCOVERY
TOXICOLOGY. ​B. D. Jeffy. Exploratory Toxicology,
Celgene, San Diego, CA.
#34 10:24 EPIGENOMICS—IMPACT FOR DRUG SAFETY
SCIENCES. ​J. Moggs. Translational Sciences,
Novartis, Basel, Switzerland. Sponsor: M. Rhodes.
#35 10:56 INVESTIGATION OF TRANSGENERATIONAL
EPIGENETIC INHERITANCE IN PRODUCT
SAFETY ASSESSMENT. ​R. J. Rasoulpour.
Developmental and Reproductive Toxicology, The
Dow Chemical Company, Midland, MI.
#36 11:28 CURRENT AND FUTURE EPIGENETIC
THERAPIES. ​N. Carey. Pfizer, Cambridge, United
Kingdom. Sponsor: M. Rhodes.
Monday Morning, March 12
9:15 AM to 12:00 Noon
Room 305
Workshop Session: Alternative Approaches to the Safety
Assessment of Natural Ingredients and Extracts in Cosmetics
Chairperson(s): Vinayak Srinivasan, L’Oréal, Clark, NJ, and Julie Skare,
Procter & Gamble, Cincinnati, OH.
Sponsor:
Association of Scientists of Indian Origin Special Interest Group
Endorsed by:
Food Safety Specialty Section
In Vitro and Alternative Methods Specialty Section
Regulatory and Safety Evaluation Specialty Section
Risk Assessment Specialty Section
Today, there is a growing consumer demand for naturally-derived ingredients
and botanical extracts such as those used as food or as flavoring agents
and those in personal care products. The principles used in safety evaluation
of foods can be extrapolated to cosmetic ingredients where the primary
route of application is dermal versus the oral route. While quality standards
exist for certification of organic and natural cosmetics, there are no globally
accepted safety assessment standards for these products. Although relatively
rare, adverse reactions to cosmetic and personal care products containing
traditional synthetic chemicals as well as botanical ingredients have been
documented in the literature. The safety assessment of plant materials for
which no or only a limited record of human exposure can be established is
complex, given that traditional, standard safety testing methods for synthetic
chemicals cannot be applied to natural plant ingredients for various reasons.
Therefore, chemical grouping, comparative, and read-across approaches as
well as the concept of the Threshold of Toxicological Concern (TTC) and
other in silico based animal alternative methodologies are pragmatic, logical,
and reliable tools for the safety assessment of plant-derived cosmetic ingredients.
MONday
Poster Sessions
Regional Interest Session
Roundtable Sessions
Symposium Sessions
Thematic Sessions
Workshop Sessions
131